ISU Abxis Co. Ltd

ISU Abxis Co., Ltd. is a biopharmaceutical company that develops and markets products for cancer and rare diseases worldwide. Its offerings include Abcertin (imiglucerase for injection) for Type 1 Gaucher disease, Fabagal (agalsidase beta for injection) for Fabry disease, and Clotinab (abciximab) as an adjunct to percutaneous coronary intervention to prevent cardiac ischemic complications. The company is also developing ISU104 for refractory cancer, ISU304 for Hemophilia B, and ISU305 for paroxysmal nocturnal hemoglobinuria. It is headquartered in Seongnam, South Korea.